Amgen (AMGN) Stock Dips While Market Gains: Key Facts

Company Performance - Amgen's stock closed at $332.80, reflecting a -0.73% change from the previous day's closing price, underperforming the S&P 500 which gained 0.03% [1] - Over the past month, Amgen's shares increased by 2.22%, while the Medical sector rose by 2.67% and the S&P 500 by 1.54% [1] - The upcoming earnings report is anticipated to show an EPS of$ 5.13, a 3.43% increase year-over-year, and revenue of $8.51 billion, indicating a 23.24% increase compared to the same quarter last year [1] Annual Estimates - For the annual period, earnings are projected at$ 19.49 per share and revenue at $33.21 billion, representing increases of +4.5% and +17.82% respectively from the previous year [2] Analyst Estimates and Valuation - Recent changes in analyst estimates for Amgen indicate a dynamic business outlook, with positive revisions suggesting optimism [2] - Amgen currently holds a Zacks Rank of 3 (Hold), with a consensus EPS projection that has decreased by 0.06% in the last 30 days [3] - The company is trading at a Forward P/E ratio of 17.2, which is lower than the industry average of 23.02, and has a PEG ratio of 2.98 compared to the industry average of 2.28 [3] Industry Context - The Medical - Biomedical and Genetics industry, to which Amgen belongs, has a Zacks Industry Rank of 79, placing it in the top 32% of over 250 industries [3] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [4]